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Abstract
Stimulated by the interest in developing gold compounds for treating cancer, gold ion–
angiotensin peptide interactions are investigated by mass spectrometry. Under the experimental
conditions used, the majority of gold ion–angiotensin peptide complexes contain gold in the
oxidation states I and III. Both ESI-MS and MALDI-TOF MS detect singly/multiply charged ions
for mononuclear/multinuclear gold-attached peptides, which are represented as [peptide+a Au
e+
(I)+b Au(III)+(e - a -3b) H] , where a,b≥0 and e is charge. ESI-MS data shows singly/multiply
charged ions of Au(I)-peptide and Au(III)-peptide complexes. This study reveals that MALDITOF MS mainly detects singly charged Au(I)-peptide complexes, presumably due to the
ionization process. The electrons in the MALDI plume seem to efficiently reduce Au(III) to Au(I).
MALDI also tends to enhance the higher polymeric forms of gold-peptide complexes regardless
of the laser power used. Collision-induced dissociation experiments of the mononuclear and
dinuclear gold-attached peptide ions for angiotensin peptides show that the gold ion (a soft acid)
binding sites are in the vicinity of Cys (a soft ligand), His (a major anchor of peptide for metal ion
chelation), and the basic residue Arg. Data also suggests that the abundance of gold-attached
peptides increases with higher gold concentration until saturation, after which an increase in
gold ion concentration leads to the aggregation and/or precipitation of gold-bound peptides.
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Introduction
Cisplatin is a platinum(II) containing chemotherapy drug
proven to be an effective treatment for several types of solid
tumors [1–3]. However, a large number of cancer patients
develop cisplatin resistance and a number of side effects are
commonly reported [1–3]. For this reason, considerable efforts
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have been made to create new effective anticancer
metallodrugs [4–7]. Since gold(III) ion is isoelec-tronic with
platinum(II) ion and it forms square-planar complexes as in
cisplatin, gold(III) compounds are explored for potential
anticancer activities. A number of gold(III) complexes with
ligands such as bipyridyls, dithiocarbamato, porphyrins, and
quinolines, which display in vitro and in vivo potent anticancer
activities and reduced systemic toxicity compared with the
cisplatin, have been synthesized [4–17]. Small peptides such as
S-phenylalanine-S-phenylalanine,
glycyl-alaline,
glycylhistidine, alanyl-phenylalanine, glycyl-S-serine, glycyl-alanylalanine, glycyl-glycyl-histidine, and glycyl-glycyl-methyonylglycyl-glycine are another class of ligands of gold(III) ion that
have been investigated for development of potential anticancer
drugs [18–24]. Although evidence [10, 11, 28] suggests that
gold-based
chemotherapy agents
seem to
induce
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antiproliferative activities against tumor cells, the main
biological targets and mechanisms responsible for gold-induced
cytotoxicity are still largely unknown. However, the
interactions between gold-based chemotherapy agents and
proteins are believed to be involved in the antitumor activity
[10, 11, 28]. Detailed information on the interaction between
gold ions and peptides/proteins is needed to shed light on the
mechanism of gold compounds’ anticancer activity and side
effects and facilitate the design of gold-based anticancer
agents.
With the development of gentle ionization techniques such
as ESI [29, 30] and MALDI [31, 32] for transferring
peptides/proteins into the gas phase without detrimental effects
on their integrity, mass spectrometry has been used
successfully to characterize metal cation (such as calcium,
cadmium, cobalt, copper, iron, magnesium, mercury, nickel,
potassium, sodium, and zinc) peptide/protein interactions [33–
46]. Data reveals some general findings such as various metal
ions may interact differently to a peptide sequence [33, 47], and
the metal cation–peptide/protein bond is believed to be
noncovalent [33]. Many MS studies suggest that the Cu-peptide
ions by MALDI is formed by a reductive process which
produces primarily Cu(I)-peptide ions, whereas ESI process
yields almost exclusively Cu(II)-peptide ions unless a solvable
copper emitter is used [34]. Collision induced dissociation
(CID), a well established tandem mass spectrometry
experiment, which produces the information of the sequence
and metal ion binding sites of a peptide, of Zn ion– and Cu
ion–angiotensin peptide complexes [34, 41, 48] indicate that
zinc and copper interaction sites are in the neighborhood of the
His and Arg residues, respectively. In addition, there are some
MS studies on the gold–protein complexes [14, 28, 33, 49–52],
disulfide bridge cleavage of gold(I) cationized peptides [53,
54], and characterization of synthetic pure gold–peptide
complexes [21–27]. Data from gold-attached glutathione
reductase or thioredoxin reductase probed by MALDI-TOF MS
speculates that Cys residue is critical to their biological
functions [14, 50]. However, X-ray crystal together with the
ESI-MS studies show that the His residue of the enzyme
cyclophilin is the gold ion binding site, despite the presence of
four Cys thiol groups in the enzyme [54]. Results from gold
bound human serum albumin and poly(ADP-ribose)
polymerase by ESI-MS speculate that both Cys and His
residues are involved in the gold ion binding [28, 51]. ESI-MS
study on the Au(I)-somatostin complex shows that Au(I)
incorporation into a disulfide bridge containing peptide is a
promising way to effect selective dissociation of disulfide
bonds [52]. In another study, ESI-MS is used to confirm the
reaction product of a synthetic Au(III)–pentapeptide
(GGMGG) complex [21]. The majority of these gold complex
studies are all aimed at the binding between gold and sulfur.
Clearly, systematic MS studies on simple Au–peptide
complexes are needed to provide a basis for the another study,

ESI-MS is used to confirm the reaction product of a synthetic
Au(III)–pentapeptide (GGMGG) complex [21]. The majority
of these gold complex studies are all aimed at the binding
between gold and sulfur. Clearly, systematic MS studies on
simple Au–peptide complexes are needed to provide a basis for
the interpretation of the interaction between gold ion and
peptide/protein. As a first step of our gold ion-peptide/protein
complex investigation, gold complexes of human angiotensin I
(Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu), human angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), CysAngiotensin II
(Cys-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), human angiotensin
IV (Val-Tyr-Ile-His-Pro-Phe), VYIHPFHL (Val-Tyr-Ile-HisPro-Phe-His-Leu), tripeptide CDR, and dipeptide DR are
probed by both ESI and MALDI-TOF/TOF MS. These choices
enable the evaluation of the interaction between gold ion and
potential metal binding amino acid residues. In addition, due to
peptides' smaller sizes, data analysis is much simpler.
Furthermore, besides angiotensin availability, its interactions
with other metals investigated by MS have been reported,
which enable the direct comparison between gold ion and other
metal interactions with angiotensin peptides. Note that
angiotensin II is a peptide hormone that causes hypertension
and has been shown to inhibit proliferation of several cell
types. Results obtained here show that singly/multiply charged
ions for the mononuclear and/or dinuclear gold-attached
peptide are detected in each complex. More abundant
formation of gold ion–angiotensin complexes are detected as
compare to the complex formation of Zn ion and Cu ion. In
addition, CID data reveals many possible gold ion binding sites
in the vicinity of Cys, His, and Arg of peptides, which is
somewhat different from Zn ion (His is the preferred anchoring
site) [48] and Cu ion (Arg is the preferred anchoring) [34, 41].

Experimental
Chemicals and Materials
All chemicals and peptides were purchased from SigmaAldrich Chemical Company (Saint Louis, MO, USA) and used
without further purification. Peptides DR, CDR, and
CDRVYIHPF (CysAngiotensin II) were synthesized inhouse
by solid phase peptide synthesis (see Supplemental Material).
Sequencing grade modified trypsin was obtained from Promega
Corporation (Madison, WI, USA).

Preparation of the Gold Ion–Peptide Complexes
Gold ion–peptide complexes were prepared by mixing 2 mM
aqueous solution of AuCl3 or AuCl with an equimolar amount
of peptide at room temperature. Concentration of gold ion
greater than ~10 mM tends to encourage the precipitation of
angiotensin I. Gold ion-angiotensin IV and VYIHPF were

J. Lee et al.: Gold Ion–Peptide Interaction
prepared by trypsin digestion of gold-angiotensin I and II,
respectively (see Supplementary Material).

Analysis of the Gold Ion–Peptide Complex by Mass
Spectrometry
Gold
ion–peptide
samples
for
MALDI-TOF
and
MALDITOF/TOF MS analyses were prepared by either mixing
equal amount of gold ion–peptide solution with matrix solution
(3–10 mg Cyano-4-hydroxycinnamic acid in 1 ml aqueous
solution of 50% acetonitrile containing 0.1% TFA) or
concentrating the gold ion–peptide complex with Millipore
(Billerica, MA, USA) C18 ZipTips and then eluted with matrix
solution. Applied Biosystems (Foster City, CA, USA)
Voyager-DE PRO MALDI-TOF or 4700 Proteomics Analyzer
MALDI-TOF/TOF MS equipped with a 337 nm pulsed
nitrogen laser was used to analyze the samples. The mass
spectrum was obtained using the delayed extraction positiveion linear and/or reflector modes by averaging 100 laser shots.
Tandem MS (MALDI-TOF/TOF) experiments were conducted
using collision energy of 1 kV with helium as the collision gas.
External mass calibration was performed using the masses of a
mixture of bradykinin fragments 1–7 at m/z 757.40, angiotensin
II (human) at m/z 1046.54, P14R (synthetic peptide) at m/z
1533.86, and adrenocorticotropic hormone fragment 18–39
(human) at m/z 2465.20. Data explorer software and MS data
analysis tools from Protein-Prospector (http://prospector.ucsf.
edu/prospector/mshome.htm) or proteomicsToolkit (http://db.
systemsbiology.net:8080/proteomics-Toolkit) were used to
analyze the data.
For ESI-MS analysis, mass spectra were obtained using
either a Thermo Electron (Waltham, MA, USA) LCQ-deca
quadrupole ion trap mass spectrometer or LTQ FT ultra hybrid
linear ion trap Fourier transform-ion cyclotron resonance (FTICR) mass spectrometer in the electrospray positive mode. A
mass accuracy of 1 ppm of the precursor ions is obtained with
FT-MS. Sample was introduced into LCQ-deca quadrupole ion
trap by direct infusion using a syringe pump with flow rate of
10 µL/min. The FT-MS spectra were obtained by electrospray
using a New Objective (Waltham, MA, USA) 4 µm glass tip
static probe with standard coating at a flow rate of 40–100
nL/min.
For HPLC-ESI-MS gold ion-peptide analysis, sample is
injected onto an Agilent (Santa Clara, CA, USA) 2.1 mm SBC18 or 75 µm Zorbax SB300 C-18 reversed-phase column
connected to a Dionex (Sunnyvale, CA, USA) Ultimate 3000
HPLC system. The samples were separated using a binary
solvent system consisting of A: 0.1% formic acid and 5%
acetonitrile and B: 0.1% formic acid and 95% acetonitrile at
flow rate of 200 µL/min or 200 nL/min. A gradient was run

from 5% B to 60%B over 30 or 60 min. The mass spectrometer
was operated in positive ion mode with the trap set to data
dependent MS/MS acquisition mode. Peaks eluted from the LC
column that had ions above 1000 arbitrary intensity units
trigger the ion trap to isolate the ion and perform an MS/MS
experiment scan after the MS full scan. The ICR cell was run
with a resolution setting of 100,000 at m/z 400 over the range
from m/z 200 to 2000. The MS was operated under the
following conditions: capillary temperature 200 °C; sheath gas
2 psi and spray voltage 2.0 kV. The Xcalibur software was
used to analyze the data.

Results and Discussion
Au Ion–Angiotensin I Complexes
MALDI-TOF MS (Figure 1) of the angiotensin I in reaction
with 1mM gold ion shows predominately singly charged intact
(m/z 1296.68; abundant), singly gold-attached [M+Au(I)]+ (m/z
1492.65; most abundant), and doubly gold-attached [M+2Au(I)
– H]+ (m/z 1688.62; less abundant) angiotensin I ions. Results
are identical no matter which gold ion is used (either AuCl3 or
AuCl). This observation in MALDI-TOF MS suggests that
MALDI process suppresses the detection of oxidation state III
and encourages the reduction of Au(III) to Au(I) by electrons in
the MALDI plume [55]. Similar findings have been reported
for Cu ion-peptide complexes [34]. Since Gold has only one
stable naturally occurring isotope 197Au with atomic mass
196.96654, the interpretation of the mass spectrum is relatively
simpler. The formula that describes the stoichiometry of the
singly charged gold-peptide complex detected by MALDI-TOF
MS is given by [M+a Au(I)+(1-a) H]+, where a=1, 2. HCl
adduct [54] of singly gold-attached (m/z 1528.65) and doubly
gold-attached (m/z 1724.62) angiotensin I ions are also
detected. In addition higher polymeric forms of goldangiotensin I complex (i.e., [aM+bAu(I)+(b -1) H]+, where
a,b≥1), such as [2 M+Au(I)]+ at m/z 2790.33 and [2 M –
3H+4Au(I)]+ at m/z 3376.24, are also detected with much lower
intensities regardless of the laser power used. This result is
consistent with the property of gold which has a tendency to
form supramolecular architecture (aurophilicity) due to its
unusually large relativistic 6 s-orbital stabilization (contraction)
[56]. In addition, this observation is similar to the results of Cu
ion–peptide complexes [34], which reports the detection of
[peptide+xCu – (x – 1)H] (x=1–6) ions. Here, multiply charged
ions are rarely detected due to the MALDI set-up (normal
MALDI instead of laserspray ionization MALDI) that was used
[57, 58]. Interestingly, doubly charged ion (m/z 746.83) of
singly gold-attached angiotensin I (m/z 1492.65) is detected
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Figure 1. MALDI-TOF of Angiotensin I in the presence of 1mM AuCl3. The matrix used for desorption is cyano-4hydroxycinnamic acid

with lower intensity. The relative abundance of the goldattached angiotensin I ion species compared with the intact ion
depends on the concentration of the gold ion. It is directly
proportional to the concentration of AuCl3/AuCl, becoming
undetectable when the concentration of gold ion is lower than
0.5 µM. However, at concentration of AuCl3 higher than 10
mM, the solution turns cloudy. The MS signals become
undetectable when the concentration of AuCl3 is higher than
250 mM, indicating that the gold-bounded species aggregate or
precipitate out of the solution.
ESI-MS (Figure 2, only relevant ions are shown) of the
angiotensin I in reaction with 1mM AuCl3 shows predominately
three kinds of ion species. (1) Intact angiotensin I ions (singly
charged, m/z 1296.68; doubly charged m/z 648.84; triply
charged, m/z 432.89). (2) Singly gold-attached angiotensin I
ions [M+Au(I)+ (e – 1) H]e+ (singly charged, m/z 1492.65;
doubly charged, m/z 746.83; triply charged, m/z 498.22) and
[M+Au(III)+(e – 3) H]e+ (singly charged, m/z 1490.65; doubly
charged, m/z 745.82; triply charged, m/z 497.55). (3) Doubly
gold-attached angiotensin I ions [M+2Au(I)+(e – 2) H]e+
(singly charged, m/z 1688.62; doubly charged, m/z 844.81;
triply charged, m/z 563.54), [M+Au(I)+Au(III)+ (e – 4) H]e+
(singly charged, m/z 1686.62; doubly charged, m/z 843.81;
triply charged, m/z 562.87), and [M+Au(III)+Au(III)+ (e – 6)
H]e+ (singly charged, m/z 1684.62; doubly charged, m/z 842.81;
triply charged, m/z 562.21). Data shows the gold ions exist in
oxidation states of III and I, indicating some reduction of
Au(III) to Au(I). Also shown are HCl adduct of singly goldattached and doubly gold-attached angiotensin I ions and
higher polymeric forms of gold-angiotensin I complexes (i.e.,
[aM+bAu(I)+cAu(III)+(e–b–3c)H]e+), such as [2 M+Au(III)]3+
at m/z 929.44 and [2 M+2Au(I,III) – H]3+ at m/z 944.76. Higher
polymeric forms of gold-angiotensin I complexes are present at
lower amount by ESI-MS than by MALDI-TOF MS. The
relationship between relative abundance of the gold-attached

ion species and concentration of AuCl3 is similar as in MALDITOF MS data described above. However, concentrations of
gold ion higher that 10 mM greatly suppress the ESI-MS
signal.
ESI-MS (Figure 3, only relevant ions are shown) of the
angiotensin I in reaction with 1 mM AuCl shows three major
kinds of ion species. (1) Intact angiotensin I ions described in
the previous paragraph. (2) Singly gold-attached angiotensin I
ions [M+Au(I)+ (e – 1) H]e+ (singly charged, m/z 1492.65;
doubly charged, m/z 746.83; triply charged, m/z 498.22). (3)
Doubly gold-attached angiotensin I ions [M+ 2Au(I)+ (e – 2)
H]e+ (singly charged, m/z 1688.62; doubly charged, m/z 844.81)
and [M+Au(I)+Au(III)+ (e – 4) H]e+ (singly charged, m/z
1686.62; doubly charged, m/z 843.80). The gold ion exists
predominately in oxidation state of I. The detection of doubly
gold-attached angiotensin I [M+Au (I)+Au(III)+ (e – 4) H]e+
indicates that some of the Au(I) disproportionate in aqueous
solution to Au(III). The HCl adduct of gold-attached angiotensin I complexes described in the previous paragraph are also
observed. The relationship between relative abundance of the
gold-attached ion species and concentration of AuCl is similar
as in MALDI-TOF MS described above.
The fact that only gold ion in the oxidation state I is
observed in MALDI-TOF MS indicates that MALDI process
suppresses the detection and promotes the reduction of higher
oxidation states. Additionally, due to the difference in the
ionization process between MALDI (addition of matrix, drying
of the sample, and desorption by a laser) and ESI, the former
tends to encourage the detection of higher polymeric forms of
gold-peptide complexes. The CID data of singly and multiply
charged angiotensin I and gold-bound angiotensin I by
MALDI-TOF/TOF (Figure 4) and ESI-MS/MS (see Figure S1
in Supplementary Material) reveals detailed information
regarding the binding between gold ion and angiotensin I. The
nomenclature for CID fragment ions, chemical structure, and
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2+

Figure 2. The ESI–MS of angiotensin I in the presence of 1mM AuCl3. Expanded regions of peaks corresponding to (a) [M+Au] ,
3+
2+
3+
(b) [M+Au] , (c) [M+2Au] , and (d) [M+2Au] ions

Figure 3. The ESI-MS of angiotensin I in the presnece of 1mM
2+
AuCl. Expanded regions corresponding to (a) [M+Au] , (b)
3+
2+
[M+Au] , and (c) [M+2Au] ions

peptide sequence of angiotensin I can be found in
Supplementary Material. Three major types of backbone bonds
may be broken upon CID, leading to six homologous series of
fragment ions (a, b, c, x, y, and z ions) [59–61]. The a-type, btype, and c-type fragment ions contain the N-terminus (Nterminal fragment ions), whereas x-type, y-type, and z-type
fragment ions contain the C-terminus (C-terminal fragment
ions). Numerical subscripts indicate the position of the amino
acid residues at the cleavage sites. Both ionization methods
produce strong signals from b, y, and a ion series in addition to
the ions formed by H2O, NH3, or CO loss. Several factors
contribute to the efficacy of the identification of gold binding
sites using the CID mass spectra. First, due to the large
relativistic effect of gold [56], gold–peptide binding is
relatively strong and survive the CID condition used here.
Second, angiotensin I contains one Arg and two His basic
residues equally distributed along the peptide chain, one Pro
residue in the middle of the peptide chain, and one Asp residue.
Note that peptide fragments containing basic residues
(protonated preferentially and retain the charge) tend to
dominate the CID mass spectrum, and the Pro residue in the
peptide sequence tends to enhance the cleavage of the peptide
bond n-terminal to it due to a higher basicity of the imide
nitrogen. Additionally, cleavage at the c-terminus of Asp
residue is favored because of protonation of the peptide bond
by the Asp side-chain carboxyl group. The majority of the a, b,
and y series are detected in this study, which facilitate the
identification of the gold binding sites. Third, angiotensin I is a
short peptide with 10 amino acid residues, which makes the
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data interpretation relatively easy. The immonium ions (a
singly side chain fragment formed by a combination of a-type
and y-type cleavage) detected in MALDI-TOF/TOF
unambiguously identified the presence of Arg (m/z 87, 100, and
112), Asp (m/z 88), Ile/Leu (m/z 86), His (m/z 110 and 138),
Phe (m/z 120), Pro (m/z 70), Tyr (m/z 136), and Val (m/z 72).
Since the peptide contains Pro amino acid residue, enhanced
signals from internal ions (double backbone cleavage of b type
and y type; contain neither N-terminus nor C-terminus) and Y
(y-2)-type ions are also detected. An abundant y9 ion at m/z
1377 is detected, which corresponds to a 115 Da loss from the
molecular ion. Considering the correlation between
complementary b and y ions (yi + b10-i– 1= MH+), this mass
difference is consistent with a b1 mass of 116 Da (Asp as the
N-terminus). CID data shows that the singly gold-attached
angiotensin I consists of three species. One species has the gold
bonded to the basic residue Arg (e.g., b2, b4, and b5 ions in
Figure 4a). The significance of the Arg residue in peptide-metal
bonding has been reported on Arg containing peptide–metal ion
interactions [41, 47]. The basic guanidinium group (pKa of
12.48) of Arg and the conjugation between double bond and
the nitrogen lone pairs most likely contribute to the binding
between Arg and gold ion (soft acid). To further confirm the
importance of the Arg residue in peptide-gold bonding,
dipeptide DR is synthesized and its gold complex is probed by
MS (see Figure S2 in Supplementary Material). Since there is
only one gold binding site in DR (Arg at position 2), as

+

expected, the CID data of the gold ion-dipeptide DR complex
shows that the gold binding site is Arg and not the NH2terminal amino group or Asp. The other two species have the
gold anchored at His residue at the sixth position (e.g.,
VYIH(Au), YIH(Au)P internal ions in Figure4a) or ninth
position (e.g., b7 and b8 ions in Figure S1b in Supplementary
Material), most likely through the N3 site of the His-imidazole
ring (the major metal anchoring site beside sulfur of Cys) [21,
26, 52, 62, 63]. Similar conclusions indicate that both His
residues are involved in the metal binding has been reported on
Zn–angiotensin I complexes [48]. Doubly gold-attached
angiotensin I also shows three species [gold bonded through
Arg and His at position 6 (e.g., a8, and y8 ions in Figure 4b),
gold bonded through the Arg and His at position 9 (e.g., y5 ion
in Figure 4b), and gold bonded through both His at positions 6
and 9 (e.g., y5, y6, y7, and y8 ions in Figure 4b)]. Note that
bidentate and/or tridentate coordination of gold ion by the Arg
and two His residues is also possible structures from these
results. The bidentate/tridentate complexes have been proposed
to be the possible structures in previous studies on Cu- and Znangiotensin complexes [34, 48]. In addition, many NMR and
X-ray studies on simple Au-peptide complexes have proposed
multidentate structures involving the amide nitrogen and the Nterminal NH2 group in addition to the amino acid residues [21–
27].
The angiotensin I solution containing gold ion is digested
with trypsin to produce gold ion–VYIHPFHL complex.

+

Figure 4. CID mass spectra (MALDI-TOF/TOF) of (a) [M+Au(I)] and (b) [M –H+2Au(I)] ions of angiotensin I
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MALDI-TOF MS and CID mass spectra (MALDI-TOF/TOF
MS) of intact and singly gold-attached VYIHPFHL are shown
in Figure S3 in Supplementary Material. Since there are two
gold binding sites in VYIHPFHL (His at positions 4 and 7), as
expected, the data is in agreement with a mixture of two gold
ion–VYIHPFHL species [gold bonded through the His at
position 6 (e.g., y2, a4, b4, and b6 ions in Figure S3c in
Supplementary Material) and 7 (e.g., y3, a5, and b5 ions in
Figure S3c in Supplementary Material)]. Same evidence of the
gold–VYIHPFHL interaction is provided in ESI-MS/MS CID
mass spectra (see Figure S4 in Supplementary Material).
Although preferential peptide bond cleavages near His,
followed by Au attachment to the pieces, can also explain the
observed fragmentation pattern, data here seems to rule out this
possibility because there is no amino acid besides His that has a
high metal affinity in both VYIHPFHL and VYIHPF (data
presented below).

Au Ion–Angiotensin II Complexes
MALDI-TOF MS (Figure 5a) of the angiotensin II in reaction
with either 1 mM AuCl3 or AuCl shows predominately singly
charged intact (m/z 1046.54; abundant) and singly goldattached [M+Au(I)]+ (m/z 1242.50; less abundant) angiotensin
II ions. The doubly gold-attached angiotensin II is barely
detected at m/z 1438.47. The lower intensity for m/z 1438.47
may stem from one less His residue (a major metal anchor site
of a peptide) compared with angiotensin I. This observation is
somewhat different from the Zn-angiotensin II complex, which
shows no difference in the relative ratio of singly Zn-attached
and doubly Zn-attached peptide between angiotensin I and
angiotensin II [48]. ESI-MS (see Figure S5 in Supplementary
Material) of the angiotensin II in reaction with either 1 mM
AuCl3 or AuCl shows predominately the intact (singly charged,
m/z 1046.54; doubly charged, m/z 523.77; triply charged, m/z
349.52), singly gold-attached [M+Au(III)+(e – 3) H]e+ (singly
charged, m/z 1240.50; doubly charged, m/z 620.75), and doubly
gold-attached [M – H+2Au(I,III)]+ (singly charged, m/z
1436.47) angiotensin II. Interestingly, the gold ion exists
predominately in oxidation state of III in ESI-MS for singly
gold-attached angiotensin II no matter which gold ion is used.
Angiotensin II in the ESI condition seems to stabilize the
highly oxidative gold(III) and promotes the disproportion of
Au(I) to Au(III). The relationship between relative abundance
of the gold-attached ion species and concentration of AuCl3 or
AuCl is similar as in angiotensin I described above.
The binding sites between gold and angiotensin II is
revealed by CID mass spectra of singly and multiply charged
singly gold-bound, and doubly gold-bound angiotensin II by
MALDI-TOF/TOF (Figure 5b and c) or ESI- MS/MS (see
Figure S6 in Supplementary Material). Since there is one less
His residue in angiotensin II than angiotensin I, as expected,

data shows that the singly gold-attached angiotensin II consists
of two species. One species has the gold bonded through the
Arg (e.g., b2, b4, and b5 ions in Figure 5b) and the other has the
gold bonded through His residue (e.g., y3, y4, and y5 ions in
Figure 5b). Since the charge is retained near the N-terminus of
the first species and C-terminus of the second species, the CID
mass spectra is dominated by b-type and y-type fragment ions
in the first and second species, respectively. Doubly goldattached angiotensin II consists of only one species with one
gold chelated with Arg and the other with His (e.g., b2, y4, and
y5 ions in Figure 5c).
The reaction solution of gold ion and angiotensin II is
digested with trypsin to produce gold ion–angiotensin IV
(VYIHPF) complex. MALDI-TOF MS and CID mass spectra
(MALDI-TOF/TOF) of intact and singly gold-attached
Angiotensin IV are shown in Figure S7 in Supplementary
Material. Since there is only one gold binding residue His in
angiotensin IV, as expected, the data interpretation is much
simpler and it is in agreement with the conclusion that His
(e.g., y3, a4, and y5 ions in Figure S7c in Supplementary
Material) is the gold ion binding site for gold ion–angiotensin
IV complexes. ESI-MS/MS (see Figure S8 in Supplementary
Material) CID data on singly and doubly charged intact and
singly gold-attached angiotensin IV further confirms this
conclusion. Interestingly, doubly gold-attached of neither
VYIHPF or VYIHPFHL is detected in this study. Unlike
angiotensin I and II situation described above, additional His
residue in VYIHPFHL does not promote additional gold ion
attachment.

Au Ion– CysAngiotensin II Complexes
Evidence indicates that sulfhydryl group of Cys is an important
Cu2+, Zn2+, and Hg2+ anchoring site of peptides [43, 64, 65] and
gold ion binding site of proteins [14, 28, 50, 51].
CysAngiotensin II (CDRVYIHPF) is synthesized and its
interaction with gold ions is probed by MS. MALDI-TOF MS
(Figure 6a) of the reaction solution containing CysAngiotensin
II in 1 mM AuCl3 or AuCl showed predominately singly
charged intact (m/z 1149.55; abundant), singly gold-attached
[M+Au(I)]+ (m/z 1345.52; less abundant), and doubly goldattached [M+2Au(I)]+ (m/z 1541.48; abundant) CysAngiotensin
II ions. Similar to the MALDI-TOF MS data, ESI-MS (see
Figure S9 in Supplementary Material) shows predominately the
intact (singly charged, m/z 1149.55; doubly charged, m/z
575.28), singly gold-attached [M+Au(I)+ (e – 1) H]e+ (singly
charged, m/z 1345.52.; doubly charged, m/z 673.27), and
doubly gold-attached [M+ 2Au(I)+ (e – 2) H]e+ (singly charged,
m/z 1541.48; doubly charged, m/z 771.24) angiotensin II ions.
Interestingly, the gold ion exists predominately in oxidation
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Figure 5. MS of angiotensin II in the presence of 1mM AuCl3: (a) MALDI-TOF MS; (b) CID mass spectrum (MALDI-TOF/TOF) of
+
+
[M+Au(I)] ; and (c) CID mass spectrum (MALDI-TOF/TOF) of [M – H+2Au(I)]

state of +I for gold-attached CysAngiotensin II with either
AuCl3 or AuCl. The ESI condition seems to stabilize the
gold(I) and promote the reduction of Au(III) to Au(I) probably
by oxidizing the sulfhydryl group of Cys. The oxidized
products of Cys are clearly present in Figure 6a at m/z 1165.55
(convert cysteine to the corresponding sulfenic acid), m/z
1181.55 (convert cysteine to the corresponding sulfinic acid),
and to a lesser extent m/z 1197.55 (convert cysteine to the
corresponding sulfonic acid). The relationship between relative
abundance of the gold-attached ion species and concentration
of AuCl3 or AuCl is similar as in angiotensin I described above.
The gold anchoring sites are identified as Cys, Arg, and His
by CID mass spectra of singly and multiply charged intact,
singly gold-bound, and doubly gold-bound CysAngiotensin II
(Figure 6b–d and Figure S10 in Supplementary Material). An
additional immonium ion detected at m/z 76, beside the
immonium ions from Angiotensin II, in MALDI-TOF/TOF
unambiguously identified the presence of Cys residue. As
expected, data shows that the singly gold-attached
CysAngiotensin II consists of three species. One species has
the gold bonded through the residue Cys (e.g., b2, RVYIH, and

y7 ions in Figure 6c), most likely through the sulfur group, and
the other two species have the gold bonded through the residue
Arg (e.g., DR(Au)VY ion in Figure 6c) and residue His (e.g.,
y3, y5, and y7 ions in Figure 6c), respectively. Data for the
doubly gold-attached CysAngiotensin II also shows three
species [gold bonded through both Cys and Arg (e.g., b3, y3,
and b5 ions in Figure 6d), gold bonded through both Cys and
His (e.g., RVY ion in Figure 6d), and gold bonded through the
Arg and His (e.g., y8-H2O ion in Figure 6d)]. ESI-MS/MS (see
Figure S10 in Supplementary Material) CID data on singly and
doubly charged intact, singly gold-attached, and doubly goldattached CysAngiotensin II further supports the conclusion. To
further confirm the importance of the Cys in gold binding, CID
(MALDI-TOF/TOF) mass spectra are obtained with a simple
synthetic tripeptide CDR and its gold complex to facilitate the
data interpretation. The CID data of the intact, singly goldbound (y1, y2, and a3 ions in Figure S11 in Supplementary
Material), and doubly gold-bound (y1, y2, and a3 ions in Figure
S11 in Supplementary Material) tripeptide CDR indicates that
Arg and Cys are the gold bonding sites and not the NH2terminal amino group or Asp.
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Figure 6. Mass spectra of CysAngiotensin II in the presence of 1mM AuCl3: (a) MALDI-TOF mass spectrum; (b) CID mass
+
+
spectrum (MALDI-TOF/TOF) of [M+H] ; (c) CID mass spectrum (MALDI-TOF/TOF) of [M+Au(I)] ; (d) CID mass spectrum
+
(MALDI-TOF/TOF) of [M – H+2Au(I)]

Conclusions
MADLI-TOF MS and ESI-MS are used successfully to obtain
valuable information about the interaction between gold ion
and angiotensin peptides. Data shows singly/multiply charged
ions of gold ion–angiotensin peptide complexes, which are
represented as [peptide+a Au(I)+b Au(III)+ (e – a –3b) H]e+,
where a,b≥0 and e is charge. Higher amount of the gold ion–
angiotensin peptide complexes occurs with higher AuCl or
AuCl3 concentration. However, too high a gold concentration
encourages aggregation and/or precipitation of gold–peptide
complex. Tandem MS data shows that Cys, His, and Arg
residues of the peptide seem to be the preferred anchoring sites
for gold ion, and the gold– peptide bond is strong enough to
survive the CID process. This study reveals that MALDI-TOF
MS mainly detects singly charged Au(I)–peptide complexes,
indicating that ion formation by MALDI process promotes the
reduction of Au(III) to Au(I). In addition, ESI-MS data shows
that gold ion in the gold ion-angiotensin peptide complexes
exists in oxidation state of I and/or III, depending on the
peptide used. Redox processes are not uncommon for gold ion–
peptide systems and gold ion containing compounds [28, 66–
68]. Gold ions in the Au–angiotensin II and Au–
CysAngiotensin II complexes exit primarily in oxidation state

of III and I, respectively. The detection of the formation of
different gold ion–angiotensin peptide complexes with different
abundances suggests that gold containing anticancer drugs may
interact differently with various peptides/proteins. This may
alter functions of peptides/proteins, which inhibits the
proliferation and differentiation of tumor cells. MS studies on
interactions between gold ion and bigger peptides/proteins, gasphase disulfide bridge cleavages with gold [53, 54], and
catalytic reactions by gold [69] are underway in this laboratory.
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